Muvvala Venkatanarayana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muvvala Venkatanarayana has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Sharath Babu Haridasyam
Department of Chemistry GITAM School of Science (Deemed to be University) Hyderabad India
7 shared publications - Niroja Vadagam
Department of Chemistry GITAM School of Science (Deemed to be University) Hyderabad Telangana India
6 shared publications - Narasimha Swamy Lakka
Department of Chemistry, School of Applied Sciences and Humanities, VIGNAN’S Foundation for Science, Technology & Research, Vadlamudi, India
4 shared publications P. K. Dubey
Department of Chemistry Jawaharlal Nehru Technological University Hyderabad Kukatpally Hyderabad Andhra Pradesh 500085 India
4 shared publications- Sanjeeva R. Chinnakadoori
Department of Analytical Research and Development Amneal Pharmaceuticals Piscataway New Jersey USA
4 shared publications - N. V. V. D. Praveen Boppy
Department of Chemistry GITAM School of Science (Deemed to be University) Hyderabad Telangana India
3 shared publications
Latest Publications
Enantiomeric Resolution of Odevixibat via Immobilized Polysaccharide Columns: Impact of NP, RP, and PO Modes on LC–MS‐Compatible Method Design
Odevixibat, a selective and reversible inhibitor of the ileal bile acid transporter (IBAT), received approval from the US Food and Drug Administration (FDA) in 2021 as the first therapeutic option for pruritus associated with progressive familial intrahepatic cholestasis (PFIC). In this study, a comprehensive chiral high‐performance liquid chromatography (HPLC) method was developed for the enantiomeric and diastereomeric separation of Odevixibat and its stereoisomeric impurities (RS, RR, SS, and SR) using immobilized polysaccharide‐based chiral stationary phases. The various chromatographic modes—including normal‐phase (NP), reversed‐phase (RP), and polar organic (PO)—were systematically investigated. Optimal resolution was achieved using a CHIRALPAK IA column (4.6 × 250 mm, 3 μm) with a mobile phase of n ‐hexane/isopropanol/methanol/trifluoroacetic acid (50:35:15:0.1, v/v/v/v) at 40°C and a flow rate of 1.0 mL/min. The method was validated according to ICH Q2(R1) guidelines. Additionally, the CHIRALPAK IM in NP mode effectively resolved closely eluting isomeric impurities, enabling preparative isolation and characterization. The optimized RP‐mode method was compatible with LC–MS detection, facilitating trace‐level impurity profiling on CHIRALPAK ID‐3 and structural characterization of stereoisomers and process‐related impurities. Thermodynamic analysis revealed entropy‐driven enantioseparations, with the NP‐HPLC method on CHIRALPAK IA showing more favorable interactions (ΔG° = 0.06) than the RP‐HPLC system (ΔG° = 1.34). The method demonstrated excellent linearity ( r 2 > 0.999) over the concentration range of 0.028–0.211 μg/mL, with recoveries between 87.1%–101.2% and precision within 0.8% RSD. High sensitivity was achieved, with LODs of 0.009–0.025 μg/mL and LOQs of 0.028–0.075 μg/mL. The method proved robust under deliberate variations in column temperature (±1°C), mobile phase composition (±2%), and flow rate (1.0 ± 0.1 mL min −1 ), showing no significant change in enantioresolution. These complementary approaches are suitable for routine quality control (CHIRALPAK IA), purification (CHIRALPAK IM) process monitoring and LC–MS impurity profiling (CHIRALPAK ID‐3), and regulatory submissions, supporting current good manufacturing practices (cGMP) in the development of Odevixibat.
Enantiomeric Resolution of Odevixibat via Immobilized Polysaccharide Columns: Impact of NP, RP, and PO Modes on LC–MS‐Compatible Method Design
Odevixibat, a selective and reversible inhibitor of the ileal bile acid transporter (IBAT), received approval from the US Food and Drug Administration (FDA) in 2021 as the first therapeutic option for pruritus associated with progressive familial intrahepatic cholestasis (PFIC). In this study, a comprehensive chiral high‐performance liquid chromatography (HPLC) method was developed for the enantiomeric and diastereomeric separation of Odevixibat and its stereoisomeric impurities (RS, RR, SS, and SR) using immobilized polysaccharide‐based chiral stationary phases. The various chromatographic modes—including normal‐phase (NP), reversed‐phase (RP), and polar organic (PO)—were systematically investigated. Optimal resolution was achieved using a CHIRALPAK IA column (4.6 × 250 mm, 3 μm) with a mobile phase of n ‐hexane/isopropanol/methanol/trifluoroacetic acid (50:35:15:0.1, v/v/v/v) at 40°C and a flow rate of 1.0 mL/min. The method was validated according to ICH Q2(R1) guidelines. Additionally, the CHIRALPAK IM in NP mode effectively resolved closely eluting isomeric impurities, enabling preparative isolation and characterization. The optimized RP‐mode method was compatible with LC–MS detection, facilitating trace‐level impurity profiling on CHIRALPAK ID‐3 and structural characterization of stereoisomers and process‐related impurities. Thermodynamic analysis revealed entropy‐driven enantioseparations, with the NP‐HPLC method on CHIRALPAK IA showing more favorable interactions (ΔG° = 0.06) than the RP‐HPLC system (ΔG° = 1.34). The method demonstrated excellent linearity ( r 2 > 0.999) over the concentration range of 0.028–0.211 μg/mL, with recoveries between 87.1%–101.2% and precision within 0.8% RSD. High sensitivity was achieved, with LODs of 0.009–0.025 μg/mL and LOQs of 0.028–0.075 μg/mL. The method proved robust under deliberate variations in column temperature (±1°C), mobile phase composition (±2%), and flow rate (1.0 ± 0.1 mL min −1 ), showing no significant change in enantioresolution. These complementary approaches are suitable for routine quality control (CHIRALPAK IA), purification (CHIRALPAK IM) process monitoring and LC–MS impurity profiling (CHIRALPAK ID‐3), and regulatory submissions, supporting current good manufacturing practices (cGMP) in the development of Odevixibat.
- 1 July 2025
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 22 (5) , 581-589
Synthesis, Characterization, and Docking Studies of 1,4-dien as a Potential Impurity in Bimatoprost Drug
Introduction: Bimatoprost synthesis, novel diene impurity, Pd/C, Docking studies, IFD calculations, prostaglandin. Methods: This impurity was controlled by employing 30% Pd/C, and the impurity level was brought to the permissible level, i.e., 0.03% (ICH guidelines) in the final drug preparation of Bimatoprost. Results: Finally, induced-fit docking calculations were performed to theoretically evaluate the binding efficiencies of these inhibitors in the crystal structure of Prostaglandin F syn-thase (PGFS). Conclusion: There are negligible differences in RMSD and docking scores between the two ligands, which amount to only 0.18 Å and 0.313 kcal/mol, respectively. These findings strongly indicate that both ligands are likely to exhibit similar biological functions and effi-ciencies.
- 1 July 2025
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 22 (5) , 581-589
Synthesis, Characterization, and Docking Studies of 1,4-dien as a Potential Impurity in Bimatoprost Drug
Introduction: Bimatoprost synthesis, novel diene impurity, Pd/C, Docking studies, IFD calculations, prostaglandin. Methods: This impurity was controlled by employing 30% Pd/C, and the impurity level was brought to the permissible level, i.e., 0.03% (ICH guidelines) in the final drug preparation of Bimatoprost. Results: Finally, induced-fit docking calculations were performed to theoretically evaluate the binding efficiencies of these inhibitors in the crystal structure of Prostaglandin F syn-thase (PGFS). Conclusion: There are negligible differences in RMSD and docking scores between the two ligands, which amount to only 0.18 Å and 0.313 kcal/mol, respectively. These findings strongly indicate that both ligands are likely to exhibit similar biological functions and effi-ciencies.
- 23 April 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (9) , e202403418
Synthesis and Biological Evaluation of 1‐(4‐(Methylsulfonyl)Phenyl)‐5‐Phenyl‐1H‐Pyrazole‐4‐Carboxamides as Epidermal Growth Factor Receptor‐Targeting Anticancer Agents
We reported the synthesis of novel pyrazole amide derivatives. The newly synthesized compounds are exhibiting in vitro anti‐cancer efficacy against MCF‐7 and A‐549 human cancer cell lines. The compounds, 6m , 6o , and 6p have greater activity against A‐549 cell lines with reference to 5‐Fluorouracil. Similarly, in vitro, epidermal growth factor receptor results revealed that compounds 6p (50% inhibitory concentration [IC 50 ] = 0.79 ± 0.04 µM) and 6m (IC 50 = 0.86 ± 0.06 µM) have shown improved activity in comparison to the standard Erlotinib (IC 50 = 0.41 ± 0.03 µM). This article systematically examines the docking studies of lead compounds 6i , 6m , 6o , and 6p , finally found compound 6o showing better binding properties (‐10.85 kcal) among all.
- 23 April 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (9) , e202403418
Synthesis and Biological Evaluation of 1‐(4‐(Methylsulfonyl)Phenyl)‐5‐Phenyl‐1H‐Pyrazole‐4‐Carboxamides as Epidermal Growth Factor Receptor‐Targeting Anticancer Agents
We reported the synthesis of novel pyrazole amide derivatives. The newly synthesized compounds are exhibiting in vitro anti‐cancer efficacy against MCF‐7 and A‐549 human cancer cell lines. The compounds, 6m , 6o , and 6p have greater activity against A‐549 cell lines with reference to 5‐Fluorouracil. Similarly, in vitro, epidermal growth factor receptor results revealed that compounds 6p (50% inhibitory concentration [IC 50 ] = 0.79 ± 0.04 µM) and 6m (IC 50 = 0.86 ± 0.06 µM) have shown improved activity in comparison to the standard Erlotinib (IC 50 = 0.41 ± 0.03 µM). This article systematically examines the docking studies of lead compounds 6i , 6m , 6o , and 6p , finally found compound 6o showing better binding properties (‐10.85 kcal) among all.
- 13 February 2024
- Published by Wiley in Separation Science Plus
- Vol. 7 (4)
Separation and quantification of organic‐related impurities of anti‐histamine drug hydroxyzine in pharmaceutical dosage forms using stability‐indicating high‐performance liquid chromatography, liquid chromatography‐mass spectrometry, and high‐resolution mass spectrometry techniques
A simple and robust high‐performance liquid chromatography (HPLC) method was developed for organic impurities of hydroxyzine hydrochloride in pharmaceuticals. The developed method was designed to estimate all organic impurities of hydroxyzine. The HPLC separation was achieved using C 18 column (150 × 3.9 mm, 5 μm) along with a binary gradient consisting of mobile phases A (0.1%, trifluoroacetic acid in purified water) and B (0.05%, trifluoroacetic acid in acetonitrile), a flow rate of 0.7–mL/min, a column temperature of 30°C and a sample temperature of 25°C. The detection wavelength used was 230 nm for the estimation of impurity‐A, impurity‐B, and all unspecified impurities and degradation products, whereas impurity‐C was quantitated using 254 nm. The stability‐indicating property of the developed HPLC technique was assessed using stress testing conditions of hydrolysis, oxidation, thermal, photo‐light, and humidity. The validation study was performed for the limit of detection and limit of quantification, linearity, and recoveries were 0.03%, 0.05%, and 0.1132–2.9920 μg/mL (R 2 > 0.999), and 84.09%–109.74%, respectively. The proposed method is highly suitable for the determination of assay, organic impurities, and degradation products of the hydroxyzine. The chemical structure of degradation product 1 (hydroxyzine N‐Oxide) and degradation product 2 (O‐Acetyl hydroxyzine) were identified with the supporting data of LC‐mass spectrometry (LC‐MS) and high‐resolution MS.
- 13 February 2024
- Published by Wiley in Separation Science Plus
- Vol. 7 (4)
Separation and quantification of organic‐related impurities of anti‐histamine drug hydroxyzine in pharmaceutical dosage forms using stability‐indicating high‐performance liquid chromatography, liquid chromatography‐mass spectrometry, and high‐resolution mass spectrometry techniques
A simple and robust high‐performance liquid chromatography (HPLC) method was developed for organic impurities of hydroxyzine hydrochloride in pharmaceuticals. The developed method was designed to estimate all organic impurities of hydroxyzine. The HPLC separation was achieved using C 18 column (150 × 3.9 mm, 5 μm) along with a binary gradient consisting of mobile phases A (0.1%, trifluoroacetic acid in purified water) and B (0.05%, trifluoroacetic acid in acetonitrile), a flow rate of 0.7–mL/min, a column temperature of 30°C and a sample temperature of 25°C. The detection wavelength used was 230 nm for the estimation of impurity‐A, impurity‐B, and all unspecified impurities and degradation products, whereas impurity‐C was quantitated using 254 nm. The stability‐indicating property of the developed HPLC technique was assessed using stress testing conditions of hydrolysis, oxidation, thermal, photo‐light, and humidity. The validation study was performed for the limit of detection and limit of quantification, linearity, and recoveries were 0.03%, 0.05%, and 0.1132–2.9920 μg/mL (R 2 > 0.999), and 84.09%–109.74%, respectively. The proposed method is highly suitable for the determination of assay, organic impurities, and degradation products of the hydroxyzine. The chemical structure of degradation product 1 (hydroxyzine N‐Oxide) and degradation product 2 (O‐Acetyl hydroxyzine) were identified with the supporting data of LC‐mass spectrometry (LC‐MS) and high‐resolution MS.
- 30 January 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (5)
Nickel‐Catalyzed Microwave‐Mediated Methylsulfonylation of Alkyl Halides
The direct nickel‐catalyzed methylsulfonylation of alkyl and aryl halides using dimethyl sulfite as the sulfur dioxide surrogate as well as the source of methyl has been achieved. This protocol provides a robust method for the synthesis of methyl sulfone derivatives under microwave irradiation in moderate to excellent yields within 60 minutes and shows excellent functional group tolerance.
- 30 January 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (5)
Nickel‐Catalyzed Microwave‐Mediated Methylsulfonylation of Alkyl Halides
The direct nickel‐catalyzed methylsulfonylation of alkyl and aryl halides using dimethyl sulfite as the sulfur dioxide surrogate as well as the source of methyl has been achieved. This protocol provides a robust method for the synthesis of methyl sulfone derivatives under microwave irradiation in moderate to excellent yields within 60 minutes and shows excellent functional group tolerance.
Separation and simultaneous estimation of enantiomers and Diastereomers of muscarinic receptor antagonist Solifenacin using stability‐indicating Normal‐phase HPLC technique with chiral stationary phase amylose tris‐(3,5‐dimethylphenylcarbamate)
The R,S‐enantiomer impurity and diastereomer impurities (S,S‐isomer and R,R‐isomer) of the solifenacin (S,R‐enantiomer) were effectively separated and quantified simultaneously utilizing normal‐phase high‐performance liquid chromatography with a chiral stationary phase consisting of amylose tris (3,5‐dimethylphenylcarbamate) coated on silica‐gel (Chiralpak, AD‐H). The enantiomeric and stereo‐selective separation was achieved within a run time of 35 minutes using a mobile phase of ‘n‐hexane, ethanol, and diethylamine’ in an isocratic elution mode with a detection wavelength of 220 nm. The validation attributes assessed were accuracy (which showed excellent recoveries between 97.5% and 100.4%) and linearity (which was proven in the range of 0.081–1.275 μg.mL−1, with a linear regression of 0.999). The stress testing experiments proved that the developed methodology by the HPLC technique has stability‐indicating characteristics, as all closely eluting peak pairs were separated well with a resolution of 2.3 and without any interference. The proposed methodology was highly efficient in separating and simultaneously determining the chiral impurities (enantiomers and diastereomers) of the solifenacin in the release and stability sample analyses of drug substances and tablets in pharmaceutical formulations.
Separation and simultaneous estimation of enantiomers and Diastereomers of muscarinic receptor antagonist Solifenacin using stability‐indicating Normal‐phase HPLC technique with chiral stationary phase amylose tris‐(3,5‐dimethylphenylcarbamate)
The R,S‐enantiomer impurity and diastereomer impurities (S,S‐isomer and R,R‐isomer) of the solifenacin (S,R‐enantiomer) were effectively separated and quantified simultaneously utilizing normal‐phase high‐performance liquid chromatography with a chiral stationary phase consisting of amylose tris (3,5‐dimethylphenylcarbamate) coated on silica‐gel (Chiralpak, AD‐H). The enantiomeric and stereo‐selective separation was achieved within a run time of 35 minutes using a mobile phase of ‘n‐hexane, ethanol, and diethylamine’ in an isocratic elution mode with a detection wavelength of 220 nm. The validation attributes assessed were accuracy (which showed excellent recoveries between 97.5% and 100.4%) and linearity (which was proven in the range of 0.081–1.275 μg.mL−1, with a linear regression of 0.999). The stress testing experiments proved that the developed methodology by the HPLC technique has stability‐indicating characteristics, as all closely eluting peak pairs were separated well with a resolution of 2.3 and without any interference. The proposed methodology was highly efficient in separating and simultaneously determining the chiral impurities (enantiomers and diastereomers) of the solifenacin in the release and stability sample analyses of drug substances and tablets in pharmaceutical formulations.
- 21 September 2023
- Published by Wiley in Separation Science Plus
- Vol. 6 (12)
Separation and quantitation of valacyclovir enantiomers using stability‐indicating chiral liquid chromatography method with a chiral stationary phase of amylose tris‐(3,5‐dimethylphenylcarbamate)
The present research developed and validated a new stability‐indicating technique for the stereo‐selectively enantiomers of the antiviral nucleoside analog Valacyclovir hydrochloride (VAL). The chiral separation was performed using normal‐phase high‐performance liquid chromatography (HPLC) with a chiral stationary phase consisting of amylose tris(3‐chloro‐5‐methylphenylcarbamate) and a mobile phase of “ n ‐hexane, methanol, ethanol, and diethylamine”, flow rate of 0.60 mL/min, column temperature of 30°C, injection volume of 10‐μL, detection wavelength of 254‐nm, and run time of 25‐min. The enantiomers (S‐enantiomer, L‐isomer, R‐enantiomer, and D‐isomer) of Valacyclovir were separated with a resolution of 4.8 and no interference. The validation parameters verified for the proposed method, linearity in a range of 0.1002–24.3486 μg/mL (0.02–4.86%) with a regression coefficient of 0.999, and the accuracy was determined with excellent recoveries ranging from 94.38%–109.97%. The concentrations established for the detection limit and quantitation limit were 0.01% and 0.02%, respectively. The forced degradation experiments were used to assess the stability‐indicating qualities. D‐Valacyclovir impurity was successfully evaluated in release and stability samples of VAL in drug substance and tablet dosage forms using the proposed normal phase chiral HPLC approach.
- 21 September 2023
- Published by Wiley in Separation Science Plus
- Vol. 6 (12)
Separation and quantitation of valacyclovir enantiomers using stability‐indicating chiral liquid chromatography method with a chiral stationary phase of amylose tris‐(3,5‐dimethylphenylcarbamate)
The present research developed and validated a new stability‐indicating technique for the stereo‐selectively enantiomers of the antiviral nucleoside analog Valacyclovir hydrochloride (VAL). The chiral separation was performed using normal‐phase high‐performance liquid chromatography (HPLC) with a chiral stationary phase consisting of amylose tris(3‐chloro‐5‐methylphenylcarbamate) and a mobile phase of “ n ‐hexane, methanol, ethanol, and diethylamine”, flow rate of 0.60 mL/min, column temperature of 30°C, injection volume of 10‐μL, detection wavelength of 254‐nm, and run time of 25‐min. The enantiomers (S‐enantiomer, L‐isomer, R‐enantiomer, and D‐isomer) of Valacyclovir were separated with a resolution of 4.8 and no interference. The validation parameters verified for the proposed method, linearity in a range of 0.1002–24.3486 μg/mL (0.02–4.86%) with a regression coefficient of 0.999, and the accuracy was determined with excellent recoveries ranging from 94.38%–109.97%. The concentrations established for the detection limit and quantitation limit were 0.01% and 0.02%, respectively. The forced degradation experiments were used to assess the stability‐indicating qualities. D‐Valacyclovir impurity was successfully evaluated in release and stability samples of VAL in drug substance and tablet dosage forms using the proposed normal phase chiral HPLC approach.
Separation and quantitative estimation of stereo‐selective enantiomers of montelukast in pharmaceutical drug substance and tablets dosage forms by using stability‐indicating normal phase‐HPLC method
Montelukast sodium (MLS) is a leukotriene receptor antagonist that relieves asthma, bronchospasm, allergic rhinitis, and urticaria. A simple, robust, and stability‐indicating normal phase high‐performance liquid chromatography method was developed to separate and quantitatively estimate the S‐enantiomer of MLS. The chiral separation was achieved using USP L51 packing material along with a mobile phase consisting of a solvent mixture (n‐hexane, ethanol, and propionic acid), a flow rate of 1.0 mL/min, a detection wavelength of 284 nm, a column temperature of 30°C and an injection volume of 20 μL. The enantiomers peaks were well separated from the peaks of the placebo, diluting solvent, MLS, and its known impurities with a resolution of more than 2.2 and with no interference. Accuracy and linearity were studied in a range of 0.36–3.597 μg/mL (0.03%–0.30%), with good recoveries between 92.5% and 96.8% and a linear regression coefficient above 0.996. The suggested chiral chromatography method is being considered as an alternative and equivalent method to the United States Pharmacopeia and European Pharmacopeia monographs. The developed method was effectively employed for the study of release and stability samples of MLS. This HPLC method is also capable of separating and estimating the stereo‐selective isomers (R‐ and S‐enantiomers) of sulfoxide impurity of MLS in pharmaceutical medicine.
Separation and quantitative estimation of stereo‐selective enantiomers of montelukast in pharmaceutical drug substance and tablets dosage forms by using stability‐indicating normal phase‐HPLC method
Montelukast sodium (MLS) is a leukotriene receptor antagonist that relieves asthma, bronchospasm, allergic rhinitis, and urticaria. A simple, robust, and stability‐indicating normal phase high‐performance liquid chromatography method was developed to separate and quantitatively estimate the S‐enantiomer of MLS. The chiral separation was achieved using USP L51 packing material along with a mobile phase consisting of a solvent mixture (n‐hexane, ethanol, and propionic acid), a flow rate of 1.0 mL/min, a detection wavelength of 284 nm, a column temperature of 30°C and an injection volume of 20 μL. The enantiomers peaks were well separated from the peaks of the placebo, diluting solvent, MLS, and its known impurities with a resolution of more than 2.2 and with no interference. Accuracy and linearity were studied in a range of 0.36–3.597 μg/mL (0.03%–0.30%), with good recoveries between 92.5% and 96.8% and a linear regression coefficient above 0.996. The suggested chiral chromatography method is being considered as an alternative and equivalent method to the United States Pharmacopeia and European Pharmacopeia monographs. The developed method was effectively employed for the study of release and stability samples of MLS. This HPLC method is also capable of separating and estimating the stereo‐selective isomers (R‐ and S‐enantiomers) of sulfoxide impurity of MLS in pharmaceutical medicine.
- 16 June 2023
- Published by Wiley in Biomedical Chromatography
- Vol. 37 (9) , e5688
Stability‐indicating normal‐phase HPLC method development for separation and quantitative estimation of S‐enantiomer of lacosamide in pharmaceutical drug substance and tablet dosage form
Lacosamide (LA) is an antiepileptic medicine that is used to treat tonic–clonic seizures, partial‐onset seizures, mental problems, and pain. A simple, effective, and reliable normal‐phase liquid chromatographic technique was developed and validated to separate and estimate the enantiomer of (S‐enantiomer) LA in pharmaceutical drug substance and drug product. Normal‐phase LC was performed using USP L40 packing material (250 × 4.6 mm, 5 μm) and a mobile phase of n‐hexane and ethanol at 1.0 ml min−1. The detection wavelength, column temperature, and injection volume used were 210 nm, 25°C, and 20 μl, respectively. The enantiomers (LA and S‐enantiomer) were completely separated using a minimum resolution of 5.8 and accurately quantified without any interference in a 25‐min run time. Accuracy study for stereoselective and enantiomeric purity trials was conducted between 10 and 200%, with recovery values ranging from 99.4 to 103.1% and linear regression values >0.997. The stability‐indicating characteristics were assessed using forced degradation tests. The proposed normal‐phase HPLC technique is an alternate approach to the official monograph methods (USP and Ph.Eur.) of LA, and it was successfully used in the evaluation of release and stability samples for both tablet dosage forms and pharmaceutical substances.
- 16 June 2023
- Published by Wiley in Biomedical Chromatography
- Vol. 37 (9) , e5688
Stability‐indicating normal‐phase HPLC method development for separation and quantitative estimation of S‐enantiomer of lacosamide in pharmaceutical drug substance and tablet dosage form
Lacosamide (LA) is an antiepileptic medicine that is used to treat tonic–clonic seizures, partial‐onset seizures, mental problems, and pain. A simple, effective, and reliable normal‐phase liquid chromatographic technique was developed and validated to separate and estimate the enantiomer of (S‐enantiomer) LA in pharmaceutical drug substance and drug product. Normal‐phase LC was performed using USP L40 packing material (250 × 4.6 mm, 5 μm) and a mobile phase of n‐hexane and ethanol at 1.0 ml min−1. The detection wavelength, column temperature, and injection volume used were 210 nm, 25°C, and 20 μl, respectively. The enantiomers (LA and S‐enantiomer) were completely separated using a minimum resolution of 5.8 and accurately quantified without any interference in a 25‐min run time. Accuracy study for stereoselective and enantiomeric purity trials was conducted between 10 and 200%, with recovery values ranging from 99.4 to 103.1% and linear regression values >0.997. The stability‐indicating characteristics were assessed using forced degradation tests. The proposed normal‐phase HPLC technique is an alternate approach to the official monograph methods (USP and Ph.Eur.) of LA, and it was successfully used in the evaluation of release and stability samples for both tablet dosage forms and pharmaceutical substances.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 20 (4) , 484-490
Synthesis of Misoprostol, and Intramolecular Isomerization of A-Type Misoprostol into B-Type Misoprostol using 1, 8-Diazabicyclo [5.4.0] undec- 7-ene (DBU)
Objective: Misoprostol is a synthetic prostaglandin that is related structurally to naturally occurring prostaglandin (PG), and it has been acknowledged as an effective inhibitor of gastric acid secretion when administered intravenously. Methods: In the present study, the novel application of 1,8-Diazabicyclo[5.4.0]undec-7-ene, a cyclic unsaturated amine [DBU] for the conversion of A-type Misoprostol (A-MP) to B-type Misoprostol (B-MP) via intramolecular isomerization. Results: The chemical structures of A-MP and B-MP were confirmed using spectral analyses of 1H-NMR, 13C-NMR and Mass spectroscopy. Conclusion: The chemical structures of A-MP and B-MP were confirmed using spectral analyses of 1H-NMR, 13C-NMR and Mass spectroscopy.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 20 (4) , 484-490
Synthesis of Misoprostol, and Intramolecular Isomerization of A-Type Misoprostol into B-Type Misoprostol using 1, 8-Diazabicyclo [5.4.0] undec- 7-ene (DBU)
Objective: Misoprostol is a synthetic prostaglandin that is related structurally to naturally occurring prostaglandin (PG), and it has been acknowledged as an effective inhibitor of gastric acid secretion when administered intravenously. Methods: In the present study, the novel application of 1,8-Diazabicyclo[5.4.0]undec-7-ene, a cyclic unsaturated amine [DBU] for the conversion of A-type Misoprostol (A-MP) to B-type Misoprostol (B-MP) via intramolecular isomerization. Results: The chemical structures of A-MP and B-MP were confirmed using spectral analyses of 1H-NMR, 13C-NMR and Mass spectroscopy. Conclusion: The chemical structures of A-MP and B-MP were confirmed using spectral analyses of 1H-NMR, 13C-NMR and Mass spectroscopy.